Filtered By:
Education: Education
Procedure: Heart Valve Surgery

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 20 results found since Jan 2013.

Stroke Heroes 2016
The American Heart Association/American Stroke Association's Puget Sound Division, along with our sponsor Medtronic, congratulates the honorees for this year's Stroke Hero Awards. We had amazing stories sent to us. Thank you to all of you who submitted a nomination. Here are some of the inspiring individuals honored this year as a Stroke Hero. AMY MOORE, Stroke Survivor Amy is described as a truly an inspiring person who has never let her stroke stop her from accomplishing her goals. Her stroke was diagnosed at six months of age and left her legally blind. Amy learned Braille during her first two years of high school an...
Source: Healthy Living - The Huffington Post - July 12, 2016 Category: Consumer Health News Source Type: news

Factors associated with non –vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Conclusions In contemporary clinical practice, up to three-fourths of patients with new-onset AF are now initially treated with a NOAC for stroke prevention. Those selected for NOAC treatment had lower stroke and bleeding risk profiles, were more likely treated by cardiologists, and had higher socioeconomic status. Trial registration clinicaltrials.gov Identifier: NCT01701817
Source: American Heart Journal - April 25, 2017 Category: Cardiology Source Type: research

Factors Associated with Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with New-Onset Atrial Fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Conclusions In contemporary clinical practice up to three-fourths of patients with new-onset AF are now initially treated with a NOAC for stroke prevention. Those selected for NOAC treatment had lower stroke and bleeding risk profiles, were more likely treated by cardiologists and had higher socioeconomic status. Trial Registration clinicaltrials.gov Identifier: NCT01701817
Source: American Heart Journal - April 4, 2017 Category: Cardiology Source Type: research

Knowledge Regarding Oral Anticoagulation Therapy among Patients with Stroke and Those at High Risk of Thromboembolic Events (P6.241)
Conclusion- Patient’s knowledge about OAT was suboptimal. The findings support the need for educational interventions to improve the knowledge regarding oral anticoagulation therapy, and thereby achieve an appropriate and safe secondary prevention of stroke.Disclosure: Dr. Bhatia has nothing to disclose. Dr. Alphonsa has nothing to disclose. Dr. Sharma has nothing to disclose. Dr. Sharma has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Bhatia, R., Alphonsa, A., Sharma, K., Sharma, G. Tags: Cerebrovascular Disease and Interventional Neurology: Thrombolysis Complications Source Type: research

COREVALVE reduces rate of death and stroke in sickest patients with aortic stenosis
In a clinical trial, a self-expanding transcatheter aortic valve met the key performance objective of reducing death and stroke in patients with severe aortic stenosis at "extreme risk" for surgery. Results of the COREVALVE EXTREME RISK trial were presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine...
Source: Health News from Medical News Today - October 31, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Post-Surgical Cognitive Outcomes (S62.001)
CONCLUSIONS:Patients who undergo AVR demonstrate persistent cognitive decline characterized by diminished learning on tests of memory and language and related to perioperative clinical stroke. These findings underscore the importance of ischemic neurologic complications of surgery and the need for improved stroke prevention and treatment strategies.Study Supported by: R01HL084375 to T.F.F.Disclosure: Dr. Giovannetti has nothing to disclose. Dr. Fanning has nothing to disclose. Dr. Ratcliffe has nothing to disclose. Dr. Price has nothing to disclose. Dr. Messe has received personal compensation for activities with GlaxoSmit...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Giovannetti, T., Fanning, M., Ratcliffe, S., Price, C., Messe, S., Selnes, O., Acker, M., Floyd, T., Szeto, W., Bavaria, J. Tags: Cerebrovascular Disease and Interventional Neurology: Cognitive and Behavioral Source Type: research

‘Ten Commandments’ of the EHRA Guide for the Use of NOACs in AF
Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF), and have emerged as the preferred choice, particularly in patients newly started on anticoagulation. Both physicians and patients are becoming more accustomed to the use of these drugs in clinical practice. However, many unresolved questions on how to optimally use these agents in specific clinical situations remain. In 2013, the first “EHRA Practical Guide” was published to provide practical guidance for situations; an update was published in 2015. Below ...
Source: European Heart Journal - April 21, 2018 Category: Cardiology Source Type: research

Can Patent Foramen Ovales Cause Problems?
Discussion During fetal development, the heart primum and secundum septa grow and overlap leaving a small but important channel between the two atria. The foramen ovale is a flap valve moving blood from the right atrium into the left atrium directly and bypassing the high pressure pulmonary system. After birth and breathing air, the neonate’s lungs open up and the pulmonary vascular resistance decreases. The left atrium now has a relatively higher pressure than the right atria, and therefore pressure on the flap valve closes the foramen ovale. Usually within 6-12 months, the fusion of the primum and secundum of the f...
Source: PediatricEducation.org - July 24, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Clinical Outcomes in 3343 Children and Adults with Rheumatic Heart Disease from 14 Low and Middle Income Countries: 2-Year Follow-up of the Global Rheumatic Heart Disease Registry (the REMEDY study).
CONCLUSIONS: -Patients with clinical RHD have high mortality and morbidity despite being young; those from low and lower-middle income countries had a poorer prognosis associated with advanced disease and low education. Programs focused on early detection and treatment of clinical RHD are required to improve outcomes. PMID: 27702773 [PubMed - as supplied by publisher]
Source: Circulation - October 3, 2016 Category: Cardiology Authors: Zühlke L, Karthikeyan G, Engel ME, Rangarajan S, Mackie P, Cupido B, Mauff K, Islam S, Daniels R, Francis V, Ogendo S, Gitura B, Mondo C, Okello E, Lwabi P, Al-Kebsi MM, Hugo-Hamman C, Sheta SS, Haileamlak A, Daniel W, Goshu DY, Abdissa SG, Desta AG, Sha Tags: Circulation Source Type: research

TCT 2015: Medtronic touts CoreValve TAVI real-world registry data
Update: Added data from study of new patient populations Medtronic (NYSE:MDT) said today it released the 1st real-world registry study of its CoreValve transcatheter aortic valve implant, reporting outcomes in-line with its clinical trials of the device. The medtech giant also released new data from 3 studies focusing on new patient populations with significant comorbidities today. Data from all of the CoreValve studies was presented at the annual Transcatheter Cardiovascular Therapeutics conference in San Franscisco. The 6,160-patient Society of Thoracic Surgeons and American College of Cardiology TVT registry study repo...
Source: Mass Device - October 13, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Catheters Clinical Trials Medtronic TCT 2015 Source Type: news

Results of the COREVALVE EXTREME RISK trial presented at TCT 2013
(Cardiovascular Research Foundation) In a clinical trial, a self-expanding transcatheter aortic valve met the key performance objective of reducing death and stroke in patients with severe aortic stenosis at "extreme risk" for surgery. Results of the COREVALVE EXTREME RISK trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
Source: EurekAlert! - Medicine and Health - October 29, 2013 Category: Global & Universal Source Type: news

Bypass surgery an “uncommon” cause of memory loss, cognitive decline
Coronary artery bypass surgery (CABG) offers a new lease on life for thousands of people each year whose hearts aren’t getting the blood they need to work properly. But it has also been blamed for “brain fog,” a loss of memory and thinking skills that follows the procedure in some people. Such brain problems are often called cognitive impairment. The operation itself may not be to blame, according to a review in today’s Annals of Internal Medicine. For the review, a team of researchers—mostly from the U. S. Department of Veteran’s Affairs—synthesized data from 17 clinical trials and four w...
Source: New Harvard Health Information - July 22, 2015 Category: Consumer Health News Authors: Howard LeWine, M.D. Tags: Heart Health bypass surgery Coronary artery bypass surgery memory loss Source Type: news

Medtronic touts CoreValve TAVR real-world registry data
Medtronic (NYSE:MDT) said today it released the 1st real-world registry study of its CoreValve transcatheter aortic valve replacement, reporting outcomes in-line with its clinical trials of the device. The 6,160-patient Society of Thoracic Surgeons and American College of Cardiology TVT registry study reported a 5.2% rate of all-cause mortality and 2.6% rate of stroke at 30 days. Those rates are consistent with the 6.9% and 5% rates, respectively, from the pivotal trial, Fridley, Minn.-based Medtronic said. “It is reassuring to see that the profound clinical results in the U.S. CoreValve Pivotal studies were replica...
Source: Mass Device - October 12, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Catheters Clinical Trials Medtronic Source Type: news

Annual Outcomes With Transcatheter Valve Therapy
Conclusions The TVT Registry provides important information on characteristics and outcomes of TAVR in contemporary U.S. clinical practice. It can be used to identify trends in practice and opportunities for quality improvement.
Source: The Annals of Thoracic Surgery - November 30, 2015 Category: Cardiovascular & Thoracic Surgery Source Type: research